AR079059A1 - ACID ((3S) -3 - (((1 - (((2R) -2-CARBOXI-4- (1-NAFTIL) BUTIL) CYCLOPENTIL) -CARBONYL) AMINO) -2-OXO-2,3,4, 5-TETRAHIDRO-1H-1-BENZAZEPIN-1-IL) ACETICO CRISTALINO, ITS PREPARATION AND USE - Google Patents
ACID ((3S) -3 - (((1 - (((2R) -2-CARBOXI-4- (1-NAFTIL) BUTIL) CYCLOPENTIL) -CARBONYL) AMINO) -2-OXO-2,3,4, 5-TETRAHIDRO-1H-1-BENZAZEPIN-1-IL) ACETICO CRISTALINO, ITS PREPARATION AND USEInfo
- Publication number
- AR079059A1 AR079059A1 ARP100104251A ARP100104251A AR079059A1 AR 079059 A1 AR079059 A1 AR 079059A1 AR P100104251 A ARP100104251 A AR P100104251A AR P100104251 A ARP100104251 A AR P100104251A AR 079059 A1 AR079059 A1 AR 079059A1
- Authority
- AR
- Argentina
- Prior art keywords
- benzazepin
- oxo
- carbonyl
- amino
- acid
- Prior art date
Links
- -1 AMINO Chemical class 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 238000005102 attenuated total reflection Methods 0.000 abstract 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 abstract 1
- 238000002329 infrared spectrum Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composicion farmacéutica y proceso de preparacion. Reivindicacion 1: Ácido {(3S)-3-[((1-[(2R)-2-carboxi-4-(1-naftil)butil]ciclopentil}-carbonil)amino]-2-oxo-2,3,4,5-tetrahidro-1H-1-benzazepin-1-il)acético cristalino, caracterizado porque es el compuesto de formula (1). Reivindicacion 2: El compuesto de acuerdo con la reivindicacion 1, caracterizado porque tiene un espectro de difraccion de rayos X de polvo que tiene reflejos característicos (expresados en grados del ángulo de difraccion 2 theta) a: 16.32, 17.05, 20.38. Reivindicacion 4: El compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 3, caracterizado porque tiene un espectro infrarrojo registrado en Reflectancia Total Atenuada que tiene bandas de absorcion características a 3426, 3267, 3060, 2936, 2876, 2598, 2456, 1736, 1639, 1597, 1512, 1487, 1459, 1441, 1424, 1391, 1315, 1232, 1191, 1137, 781, 773, 735, 713, 670 cm-1. Reivindicacion 5: El compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizado porque tiene un espectro 13C-NMR en estado solido con desplazamientos característicos (expresados en ppm con relacion a glicina (delta c = 176,03 para la resonancia C=O)) a: 177.0, 176.0, 174.7, 172.2, 169.7, 138.9, 136.4, 133.6, 131.5, 130.2, 127.8, 126.5, 125.3, 124.2, 123.2, 121.9, 55.1, 51.0, 41.9, 40.8, 38.5, 37.1, 28.4, 25.9, 23.1, 21.1 +- 0.1 ppm.Pharmaceutical composition and preparation process. Claim 1: {(3S) -3 - [((1 - [(2R) -2-carboxy-4- (1-naphthyl) butyl] cyclopentyl} -carbonyl) amino] -2-oxo-2,3 acid, Crystalline 4,5-tetrahydro-1H-1-benzazepin-1-yl), characterized in that it is the compound of formula (1). Claim 2: The compound according to claim 1, characterized in that it has a powder X-ray diffraction spectrum having characteristic reflections (expressed in degrees of diffraction angle 2 theta) at: 16.32, 17.05, 20.38. Claim 4: The compound according to any one of claims 1 to 3, characterized in that it has an infrared spectrum recorded in Attenuated Total Reflectance having characteristic absorption bands at 3426, 3267, 3060, 2936, 2876, 2598, 2456, 1736, 1639, 1597, 1512, 1487, 1459, 1441, 1424, 1391, 1315, 1232, 1191, 1137, 781, 773, 735, 713, 670 cm-1. Claim 5: The compound according to any one of claims 1 to 4, characterized in that it has a solid state 13C-NMR spectrum with characteristic shifts (expressed in ppm relative to glycine (delta c = 176.03 for resonance C = O)) a: 177.0, 176.0, 174.7, 172.2, 169.7, 138.9, 136.4, 133.6, 131.5, 130.2, 127.8, 126.5, 125.3, 124.2, 123.2, 121.9, 55.1, 51.0, 41.9, 40.8, 38.5, 37.1, 28.4 , 25.9, 23.1, 21.1 + - 0.1 ppm.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09178226 | 2009-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079059A1 true AR079059A1 (en) | 2011-12-21 |
Family
ID=41682516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104251A AR079059A1 (en) | 2009-12-07 | 2010-11-18 | ACID ((3S) -3 - (((1 - (((2R) -2-CARBOXI-4- (1-NAFTIL) BUTIL) CYCLOPENTIL) -CARBONYL) AMINO) -2-OXO-2,3,4, 5-TETRAHIDRO-1H-1-BENZAZEPIN-1-IL) ACETICO CRISTALINO, ITS PREPARATION AND USE |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR079059A1 (en) |
| TW (1) | TW201127815A (en) |
| WO (1) | WO2011069944A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19510566A1 (en) | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepine, benzoxazepine and benzothiazepine N-acetic acid derivatives and process for their preparation and medicaments containing these compounds |
| DE19638020A1 (en) | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Gastrointestinal blood flow promoting drugs |
| US7232813B2 (en) | 2004-01-12 | 2007-06-19 | Solvay Pharmaceuticals B.V. | Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders |
| PL1706121T3 (en) | 2004-01-12 | 2009-02-27 | Turski Lechoslaw | Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders |
| AU2005315608B2 (en) | 2004-12-15 | 2011-03-31 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors |
-
2010
- 2010-11-18 AR ARP100104251A patent/AR079059A1/en unknown
- 2010-12-06 TW TW099142340A patent/TW201127815A/en unknown
- 2010-12-06 WO PCT/EP2010/068932 patent/WO2011069944A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW201127815A (en) | 2011-08-16 |
| WO2011069944A1 (en) | 2011-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011060304A3 (en) | Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions | |
| IL214236A0 (en) | Heterocyclic compounds, pharmaceutical compositions containing them, and their use as inhibitors of the glycine transporter 1 | |
| MY180672A (en) | Ace2 polypeptide | |
| PL1913138T3 (en) | Processes for the manufacture of pancreatin powder with low virus content | |
| SI1695710T1 (en) | Crystalline form beta-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it | |
| DE602007014411D1 (en) | MEDICAL DISPENSING SYSTEM WITH LOCKING RING WITH L-SHAPED NUTS | |
| WO2006052968A3 (en) | Stabilized ramipril compositions and methods of making | |
| WO2010003992A8 (en) | Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer | |
| AR081324A1 (en) | PRODUCTION OF HIGH DENSITY UNIFIED COMPOSITIONS | |
| WO2010038237A3 (en) | Compositions exhibiting delayed transit through the gastrointestinal tract | |
| EA200870422A1 (en) | IMPROVED DISTRIBUTION DEVICE | |
| EA201070326A1 (en) | PREPARATION AND COMPONENT, INTENDED FOR ADDITION TO A TOBACCO PRODUCT | |
| ZA200807024B (en) | Alpha crystaline form of the arginine salt of perindopril, process for preparing it, and pharmaceutical compositions comprising it | |
| CA2634695A1 (en) | Assembling a packaged bundle using an adjustable multi-shelved product transporter | |
| AR079059A1 (en) | ACID ((3S) -3 - (((1 - (((2R) -2-CARBOXI-4- (1-NAFTIL) BUTIL) CYCLOPENTIL) -CARBONYL) AMINO) -2-OXO-2,3,4, 5-TETRAHIDRO-1H-1-BENZAZEPIN-1-IL) ACETICO CRISTALINO, ITS PREPARATION AND USE | |
| NO20084942L (en) | Procedure for increasing or affecting the shelf life of agricultural products producing ethylene during transport and / or storage | |
| MX2011007771A (en) | Pharmaceutical compositions with superior product performance and patient compliance. | |
| WO2010063667A3 (en) | Pharmaceutical composition comprising ezetimibe and simvastatin | |
| EA201100104A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING STATIN | |
| GR1006879B (en) | Improved pharmaceutical composition containing hmg-coa reductase inhibitor and method for the preperation thereof | |
| WO2010034825A3 (en) | Novel antibodies recognizing native annexin a3 | |
| ATE536342T1 (en) | NEW CARBAMOYL GLYCINE DERIVATIVES | |
| WO2009120378A3 (en) | Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates | |
| WO2009034464A3 (en) | Indole related compounds with physiological activity | |
| WO2012034201A3 (en) | Creatine-containing food supplement composition, method for preparing same and food supplement dosage form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |